Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine
Copyright © 2020 Elsevier Ltd. All rights reserved..
Vaccine solutions rarely reach the public until after an outbreak abates; an Ebola vaccine was approved 5 years after peak outbreak and SARS, MERS, and Zika vaccines are still in clinical development. Despite massive leaps forward in rapid science, other regulatory bottlenecks are hamstringing the global effort for pandemic vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Trends in biotechnology - 38(2020), 9 vom: 01. Sept., Seite 943-947 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pregelj, Lisette [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 01.09.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tibtech.2020.06.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311788467 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311788467 | ||
| 003 | DE-627 | ||
| 005 | 20231225143016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tibtech.2020.06.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311788467 | ||
| 035 | |a (NLM)32600777 | ||
| 035 | |a (PII)S0167-7799(20)30168-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pregelj, Lisette |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Vaccine solutions rarely reach the public until after an outbreak abates; an Ebola vaccine was approved 5 years after peak outbreak and SARS, MERS, and Zika vaccines are still in clinical development. Despite massive leaps forward in rapid science, other regulatory bottlenecks are hamstringing the global effort for pandemic vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a innovation speed | |
| 650 | 4 | |a regulation | |
| 650 | 4 | |a vaccine development | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Ebola Vaccines |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Hine, Damian C |e verfasserin |4 aut | |
| 700 | 1 | |a Oyola-Lozada, Maria G |e verfasserin |4 aut | |
| 700 | 1 | |a Munro, Trent P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in biotechnology |d 1988 |g 38(2020), 9 vom: 01. Sept., Seite 943-947 |w (DE-627)NLM012637521 |x 1879-3096 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:9 |g day:01 |g month:09 |g pages:943-947 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tibtech.2020.06.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 9 |b 01 |c 09 |h 943-947 | ||